Latest Clinical News

FDA Approves Nivolumab and Ipilimumab Combination for Advanced Kidney Cancer (02-18-2019)

The Food and Drug Administration (FDA) approved the immunotherapy drugs Opdivo and Yervoy in combination as an initial, or first-line, treatment for patients with advanced kidney cancer whose disease has an intermediate or poor prognosis. This is the... Continue Reading

Keytruda Plus Inlyta Improves Survival Compared ot Sutent for Treatment of Advanced Kidney Cancer (02-18-2019)

Results from the randomized, phase III KEYNOTE-426 clinical trial show that first-line therapy with a combination of the PD-1 targeted immunotherapy Keytruda (pembrolizumab) and the VEGF-targeted tyrosine kinase inhibitor Inlyta (axitinib) improved overall... Continue Reading

Adjuvant Taxotere Doesn’t Improve Outcomes in Early Stage High Risk Prostate Cancer (02-11-2019)

Patients with high-risk, non-metastatic prostate cancer saw no survival advantage and no delay in metastases with the addition of adjuvant docetaxel to androgen deprivation therapy (ADT), according to the results of a pivotal clinical randomized trial... Continue Reading

Personalized Vaccine to be Tested in Patients with Kidney Cancer (01-29-2019)

By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving... Continue Reading

TVEC-Genetically Modified Virus Injection into Tumor – A Valid Treatment for Metastatic Melanoma (01-25-2019)

Results published in the Journal of the American College of Surgeons show sustained effectiveness of disease response and favorable side effect profile. CHICAGO (January 25, 2019): Injection of a genetically modified virus that induces the body’s own... Continue Reading

Targeted Radiation with 177Lu-PSMA-617 is Promising Treatment for Advanced Prostate Cancer (12-31-2018)

177Lu-PSMA-617 is a member of a new class of drugs that deliver radiation directly to tumor cells to obliterate them. These targeted radiation treatments consist of a radioactive isotope attached to a molecule that specifically targets tumor cells. In... Continue Reading

Immunotherapy Offers New Hope in Triple Negative Breast Cancer (12-28-2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results... Continue Reading

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (12-21-2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past... Continue Reading

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer (12-19-2018)

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment... Continue Reading

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (12-12-2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine... Continue Reading

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (12-11-2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium,... Continue Reading

Choice of surgery may affect quality of life for young breast cancer survivors (12-10-2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center.... Continue Reading

Next Page »